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Substance Use in the Era of COVID-19: A Synthesis of the Problem,
Sequelae, and Viable Strategies for the Future
Introduction
The COVID-19 pandemic has highlighted the chronic problem of
substance use as a public health epidemic in the United States. Our nation
has been significantly impacted by the pandemic with more than 579,000
Americans dead and over 32.5 million infected as of May 5, 2021.1 Ongoing
national trauma continues to impact individuals, families, and communities
with many wondering the extent to which the nation will be negatively
impacted by related outcomes such as increased substance use, completed
suicides, child abuse, and domestic violence. This syndemic, an interaction
of biologic and social conditions, has highlighted the need to address
vulnerabilities that lead to poor health outcomes.2,3 Substance use has also
been exacerbated across all regions by COVID-19, and both have been
inadequately addressed by healthcare systems.4,5 Additionally, community
organizations and partnerships are struggling to meet demands with
inadequate funding, outdated legislation, and overtaxed human resources.6
A number of negative sequelae have already resulted from COVID-19 such
as worsening health disparities and health outcomes that could be mitigated
with implementation of comprehensive evidence-based strategies to build
the necessary infrastructure and prepare for disasters such as the current
syndemic. 7
This article highlights key findings regarding the prevention,
assessment, and treatment of substance use during the coronavirus
pandemic; negative sequelae associated with public health
recommendations instituted to reduce the risk of coronavirus (eg, social
distancing); and anticipated future sequelae. As vaccines and some
treatments are now widely available, the need to socially distance or isolate
to prevent the spread of the virus may soon diminish but the current public
health measures are also well-known risk factors for substance use,
violence, and suicide and these sequelae will need to be appropriately
addressed.8,9 As researchers and practitioners continue to gather local
information to determine how health outcomes have changed from prepandemic conditions, it will be years before definitive data are available
about COVID-19's impact on measures of safety and violence.10 An
example of how grassroots community organizations can pivot to meet the
needs of those in recovery is provided. Policy implications for current and
predicted challenges are also discussed to provide context for further
research.
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Methods
Literature Synthesis Process
An initial literature search was conducted using Medline Full Text,
APA PsycInfo, and SocINDEX with Full Text databases. The searches used
medical subject headings (MeSH) and keywords related to population,
COVID-19, social isolation, substance use, domestic violence, child abuse,
depression, and anxiety. Search terms included: adult, adolescent, child,
COVID, COVID-19, SARS-CoV2, coronavirus, isolation, solitude,
loneliness, confinement, aloneness, quarantine, withdrawal, seclusion,
substance use, domestic violence, child abuse, depression, and anxiety.
Results were limited to peer-reviewed journals and English language, and
a total of 382 peer-reviewed journal articles were found. Titles and abstracts
were reviewed for all the identified journals; one duplicate was found and
removed, resulting in 32 articles identified as relevant.
Articles were removed if they did not directly address the problem of
substance use during the time of COVID-19. Of the 382 identified articles,
349 were removed because they did not address COVID-19, results were
not generalizable, or they did not address substance use during the time of
COVID-19 after further review of the full text. Additional articles were
identified from ancestry searches of the included articles and open-source
articles not previously identified through the systematic literature review. As
data about COVID-19, substance use, and sequelae were updated in real
time, the authors included the relevant information in this article.
Substance Use in the Era of COVID-19: The Current Problem
Overdose Deaths
The Centers for Disease Control and Prevention (CDC) recently
released drug-overdose death data that showed a 28.8% increase in
predicted drug overdoses during the 12 months preceding September
2020.11 Initial numbers indicated that deaths involving fentanyl (including
illicitly manufactured fentanyl), cocaine, and methamphetamine continue to
increase as polysubstance use is common.12 Some suggest that the policy
of limiting carfentanyl was primarily responsible for the small overdose
decline from 2017 to 2018.13 However, synthetic opioids including illicitly
manufactured fentanyl and co-involving psychostimulants were already
primary drivers of overdose deaths in 2017.14 Psychostimulants with abuse
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potential include prescription stimulants as well as illicit drugs such as
methamphetamine, cocaine, and ecstasy.
In May 2020, the Overdose Detection Mapping Application Program
(ODMAP) reported that more than 20 states had increases in opioid-related
mortality since COVID-19 began to spread in the United States 15. As the
nation becomes more sophisticated in its approach to surveillance and
monitoring, it will be able to prepare communities for emerging drug trends
such as the distinct and predictive waves of the opioid crisis. The first wave,
which started in the 1990s with prescription opioid medications, moved into
the second wave with a rise in overdose deaths involving heroin, and the
third wave starting in 2013 with increased overdoses involving fentanyl and
its illicitly manufactured analogs.12 As the crisis moves into its fourth wave-an increased use of psychostimulants--communities and coalitions of key
stakeholders will ideally be able to implement effective prevention,
treatment, and recovery services to minimize the drugs’ impact.16
Alcohol Use
As the pandemic unfolds with the continuing drug epidemic in the
background, there is a legitimate concern about increased use of other legal
and illegal substances that would significantly affect our nation’s mental
health. Specifically, indications are that alcohol use has increased both in
the amount of alcohol purchased as well as in self-reported changes in
alcohol use.17 In a study that measured three main indicators of alcohol use
over time (February 2020 to April 2020), the authors reported that
respondents who increased their consumption were mostly those who
drank more than their usual quantity and those who were not initially
drinking more than recommended guidelines in the month of February. The
largest increases in all three outcome measures were observed in the
western US (including Alaska and Hawaii) when compared to other US
regions. 17 In September 2020, the National Institute on Alcohol Abuse and
Alcoholism (NIAAA) reported an increase of up to 37% in monthly alcohol
sales (spirits, wine, beer). Among the 12 states with reported data, 11 states
reported increases compared to the prior 3-year average for September and
1 state reported net decreases.18
Outcomes of RAND’s American Life Panel indicated that the overall
frequency of alcohol consumption increased by 14% among adults over age
30, compared to the same time in 2019.19 While health-related
consequences because of sustained alcohol use may occur, there is also
concern about alcohol’s impact on psychological symptoms such as
depression and anxiety. 20
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Marijuana
Similarly, among emerging adults who used alcohol and cannabis
prior to the pandemic, those who self-isolated during the pandemic
increased their cannabis use by 20% compared to those who did not selfisolate.21 Of note is the increasing use of marijuana among young adults
ages 18-25 that was noted prior to the pandemic. In this age group, 20.8%
reported past month use of marijuana in 2016 with a 23% increase in 2019.
The reported daily use of marijuana for this young-adult age group
significantly increased from 6.4% in 2016 to 7.5% in 2019. The use of
methamphetamine among those over age 25 also showed significant
increases from 0.5% in 2016 to 0.8% in 2019.21
While maternal substance use has serious risks for the pregnant
woman and her fetus, society still struggles with ways to best deal with this
complicated issue. The directives of the lockdown and quarantine orders
suggest that consequences such as reduced accessibility to health
resources and family and work stressors could impact the health of all
females, with pregnant women being particularly vulnerable. This may be
especially true if they are at high risk for substance use or are in early
recovery.
The percentage of pregnant women reporting daily or almost-daily
use of marijuana rose from 1.5% in 2018 to 1.7% in 2019, representing
about 36,000 pregnant woman using marijuana.22 Pregnant women are
usually highly motivated to stop using alcohol and substances during
pregnancy, but many are not willing to disclose their use because of fear of
being judged, reprimanded, or possibly alerting law enforcement. 23 Many
leaders discuss the importance of universal screening for alcohol and all
substance use with all pregnant woman at every appointment. Because
there is no known safe amount of substance use during pregnancy, early
identification of any use and appropriate intervention may decrease the risk
of substance-related birth defects and developmental disabilities. 23
Other Drugs
Deaths involving psychostimulant use have mirrored deaths from
opioids since 2009 and are now considered the fourth wave, as cocaine and
methamphetamine deaths became more prevalent than prescription opioids
or heroin deaths in 2019.24 Among clinical drug testing samples from a
nationwide laboratory, there was no increase in positive findings for
cocaine, amphetamines, oxycodone, or tramadol compared to findings prior
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to the pandemic.25 Among tests that were positive for nonprescription
fentanyl, however, there were significant increases for amphetamines
(89%) and cocaine (34%).25 One of the challenges with psychostimulant
use is that there are no approved drug treatments as there are for alcohol,
nicotine, and opioids. Additionally, for drug tests that were processed and
positive for nonprescribed fentanyl, there was a 39% increase in opiates. 25
Negative Consequences
Psychological symptoms during COVID-19 have significantly
increased.26 Causes for this are not clear, but previous literature suggests
that personal and economic upheaval, social isolation, disruptions to
routines of daily life, grief over the deaths of loved ones, decreases in
positive emotions, fear of uncertainty, and trauma related to these
experiences during COVID-19 contribute to the rise in depression, anxiety,
suicidal ideation, and stress.26-29. Of particular importance is identification
of young adults and subpopulations such as those who identify as nonbinary
gender and who are particularly vulnerable to social and psychological
disruptions resulting from recommendations and policies meant to protect
the population from COVID-19.30
As youth potentially experience more adverse childhood events as a
result of the pandemic (eg, loss of parent, child abuse and neglect), there
is concern that the national suicide crisis will be accelerated.31 Early
indications from U.S. cohort studies of adults in April, May, and June 2020
suggest elevated adverse mental health conditions associated with COVID19. Younger adults, racial and ethnic minorities, essential workers, and
unpaid adult caregivers report experiencing disproportionately worse
mental health outcomes including increased substance use and elevated
suicidal ideation.32 In March 2020, a national sample of adults revealed high
levels of depression and fear, particularly in areas with more COVID-19.33
Data from the 2019 National Survey of Drug Use and Health
indicates that substance use disorders are associated with suicidal
thoughts, plans, and attempts among adults age 18 and older. That is, those
with a substance use disorder (SUD) are more likely to have thoughts of
suicide, develop a plan, and make an attempt than those without SUD.22 In
2018, there were 1.4 million suicide attempts in the US and suicide resulted
in 2 1/2 times more deaths than homicide.34,35 Between 1999-2018, the
suicide rate in the United States increased 35% and was the second leading
cause of death among those ages 10-34 years.36
One consequence of changing alcohol and drug use trends is
historically rising mortality rates for middle-aged adults; particularly deaths
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from poisoning, suicide, chronic liver disease, and cirrhosis.37 These
“deaths of despair” are fueled by drug-related deaths that have increased
dramatically since the early 1990s. As mental health and substance use
disorders continue to negatively impact individuals and families, many are
further impacted by tragic responses such as suicide attempts and
completed suicides. There are many shared risk factors among substance
misuse, addiction, and suicidal behaviors. While researchers highlight that
no one risk factor reliably predicts who will die by suicide, the emergence of
COVID-19 has potentially created a perfect storm of salient risk factors.34
This is particularly important because social isolation and related feelings
of loneliness are the main risk factors associated with suicidal outcomes in
the US and throughout the developed world.38 Steps that policymakers,
health care leaders, and organizational leaders can take to mitigate suicide
risk during and after the pandemic are outlined in a special commentary
provided by the American Foundation for Suicide Prevention (AFSP).39
The Fifth Wave
Multiple studies of adverse childhood experiences have documented
the impact of household function and child abuse on health behaviors and
outcomes later in life.40,41The significant increase in psychological distress,
fear, substance use, suicide, domestic violence, and loss of healthcare
coverage highlights the need to prepare to address these issues now,
during this syndemic. Delaying prevention efforts until the children and
adolescents of today begin to exhibit substance use, depression, anxiety,
and generational trauma will cost more in terms of social decay, healthy life
years lost, increased early mortality, and overall healthcare costs in the
future.10 Increasing support for all caregivers to provide safe and stable
environments now would be a small investment that would yield large
benefits in the future.42 Preventing the fifth wave will take a concerted effort
to address the events, individual experiences, and the effects across all
sectors of the social-ecological framework to address this complex issue.43
Implementing programs in schools and childcare programs to build
protective factors is a first step. Screening for substance use in middle and
high schools may help identify adolescents who are beginning to use or
misuse substances and provide an opportunity to intervene. Anticipating the
future outcomes of today’s youth will help guide strategic interventions to
prevent subsequent increases in negative outcomes.30
Enhance Strategies in the Time of COVID-19
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An increasing number of peer-reviewed articles attribute increased
substance use to the pandemic. Many reports (as an open letter or
commentary) rely on convenience samples with little generalizability
beyond the specified location.32,44 The National Institute on Drug Abuse
(NIDA) has called on researchers to adapt their projects to further
characterize the impact of COVID-19 on substance use and to investigate
the intersection with the pandemic particularly in vulnerable populations.45
Ensuring a consistent framework in how prevention and intervention
activities and subsequent research are conceptualized will allow for
progress across the Institute of Medicine’s continuum of care.46

Figure 1. Continuum of Care

(SAMHSA, 2016)

The Continuum of Care, as described by the Institute of Medicine and
operationalized by the Substance Abuse and Mental Health Services
Administration (SAMHSA), includes promotion, prevention, treatment, and
recovery (Figure 1).46 Comprehensive prevention and intervention efforts
require implementation of evidence-based programs and policies across
different levels of influence. In the time of COVID-19, the prioritization of
using established evidence-based initiatives at all levels is paramount.
However, there is also an opportunity to innovate using new ideas and
technologies to impact the changing conditions of the environment. If this
challenge is not met, the negative sequelae will likely manifest in the next
generation of young adults as substance use, depression, suicide, domestic
violence, child maltreatment, and chronic medical conditions. The financial
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and human cost of not implementing primary prevention and universal
strategies is significant. As researchers and practitioners begin to innovate,
it is important not to lose sight of how the pandemic has created conditions
that may provide a window to new or improved prevention strategies.10,42
One consequential change in service delivery during the pandemic
has been expanded use of telehealth options. Telehealth delivery of
medication-assisted treatment (MAT) and therapy improves access to
treatment, and patients report high satisfaction.47 However, the authors
argue that large-scale randomized controlled trials need to be done. Rural
areas often lack access to specialty care such as behavioral health
treatment for substance use disorder. In a study of emergency departments
in critical access hospitals, wait times decreased from 27 minutes prior to
tele-behavioral health access to 12 minutes after instituting tele-behavioral
health.48 A recent qualitative study included healthcare providers from
various regions and settings across the US. Many providers reported that
telehealth improved the quality of the patient-provider interaction, reduced
wait times, and reduced the number of missed appointments.49 However,
other providers in this study noted that the lack of structure and
accountability negatively impacted care. Additionally, challenges with
utilizing technology and poor connectivity were reported. Clearly, more
research is needed as additional risk factors and barriers to access for
behavioral health services have changed during COVID-19.50 With the rapid
adoption of telehealth services, many providers simply switched to
telehealth without modifying the policies and procedures that can maximize
this delivery method. Studies that examine delivery and receipt of care
would be valuable to better understand the safest and most effective
delivery process as healthcare services will likely not return to pre-COVID19 delivery models.51
Building on the transdisciplinary partnerships of the National
Institutes of Health’s HEAL Initiative (Helping End Addiction Long-term),
existing models of large-scale collaboration could be leveraged for
additional prevention research.52 While the HEAL Initiative focuses on
reducing opioid misuse and addiction, of critical importance are
collaborating to enhance prevention research, translating research into
practice, and building readiness for leadership in new areas. With a goal of
creating conditions to ensure improved health and wellness in the next
generation, researchers can develop prevention strategies to build safe and
supportive physical environments, improve tertiary and clinical care, and
address social and economic disparities that worsen outcomes for all.
Although there is a need to focus on preventing potential negative
sequelae of COVID-19 on substance use, this is also an opportunity to focus
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more heavily on health promotion and prevention measures such as
universal and selective screenings to prevent sequelae from substance use
in children and families. These negative sequelae will likely manifest in the
next generation of young adults as substance use, suicide, depression,
domestic violence, child abuse and neglect, and chronic medical conditions
if they are not addressed now. 10 It is not enough to focus on costly,
downstream tertiary prevention strategies. The most impact and the least
economic and societal cost will be realized through primary prevention
efforts that will reduce the demand for secondary and tertiary
interventions.53
Innovative Actions to Address Negative Sequelae
The COVID-19 pandemic has already exacted a staggering toll in the
US with an untold number of people experiencing negative sequelae. While
public health and government responses may be one part of the solution,
the syndemic has created opportunities to develop and support innovative
solutions to mitigate current and future negative outcomes.54,55
In this section, recovery community organizations (RCOs) are
highlighted as a rapid-response, grassroots movement designed to support
individuals and families experiencing substance use and misuse.56
Additional community responses may include disaster and emergency
preparedness that focuses on trauma-informed care principles and
practices. Part of being fully prepared requires an intense focus on the fifth
wave of this syndemic: increased adverse childhood experiences.10
Children who are no longer receiving their education in face-to-face
classroom environments or who are in prolonged contact with abusers are
more likely to misuse substances and perpetuate violence as they reach
adolescence and young adulthood.40, 41 Increased social vulnerabilities
further marginalize the most at-risk populations.57
Decades of research have identified the importance of selecting and
implementing programs or interventions that are consistent with prioritized
needs for specific populations. Decision support systems that help guide
the selection of interventions have been widely used to promote evidencebased programming/practices across many disciplines.58,59 As the
implementation science literature documents specific factors related to
high-quality implementation, researchers have studied how the concept of
organizational readiness might be a precursor to implementation of an
innovation (eg, new program, policy, practice, or process).60-63 The
construct of organizational readiness may be useful to local and state
governments, health and education agencies, foundations, and researchers
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as they consider new ways to implement, scale up, and adapt effective
innovations.
Researchers, such as those at the National Collaborating Centre for
Methods and Tools (NCCMT) have worked toward a common definition of
organizational readiness and refined measurement tools for use.64 As
agencies consider what strategies they may want to implement or models
they may want to scale up to reduce risk, readiness may further inform their
selection. Wandersman and his colleagues have proposed the readiness
rubric of Readiness = Motivation × General Capacity and InterventionSpecific Capacity (R=MC2).65,66 R=MC2 defines readiness as the interplay
between motivation, innovation-specific capacity, and general capacity. The
components are assumed to have a multiplicative relationship, where if one
of the components is low or nonexistent, the organization or community is
not fully ready for an innovation. Motivation is the degree to which an
organization wants and is committed to the innovation taking place.
Innovation-specific capacities are the conditions necessary for a specific
innovation (program, policy, practice, or process) to be implemented with
quality. General capacity refers to the overall ability of an organization to
function successfully on a day-to-day basis. Together, the three
components represent a comprehensive and actionable model for
organizational readiness.65,67,68 Each of the three readiness components
comprises several subcomponents that can be enhanced and measured for
change. The R=MC2 model has two primary readiness assessment tools:
the Readiness Diagnostic Scale (RDS) and the Readiness Thinking Tool
(RTT). Both are designed to assess organizational readiness using the
R=MC2 framework. Usually, leadership (in collaboration with the readiness
team) determines which assessment tool is best for a specific organization.
Bright Spot: Recovery Community Organizations
As communities work to build capacities and infrastructure to deal
with crises such as the syndemic, one model of community success is the
recovery community organization. RCOs are independent, nonprofit
organizations that are peer led with a focus on multiple pathways to
recovery from addiction. Staff and board members are recovery allies and
include those in long-term recovery. One example of an RCO is The
Courage Center in Lexington, South Carolina, which continued working
through the pandemic with significant increases in the demand for peer
recovery support for youth, young adults, and parents/caretakers. To meet
the increasing need, the organization adopted a hybrid model of peer
support that includes both in-person and virtual platform options. Additional

https://digitalcommons.library.tmc.edu/childrenatrisk/vol11/iss2/7

10

Bates and Imm: Substance Use in the Era of COVID-19

services included mutual aid groups, telephone case monitoring, and other
support services for individuals and families on their recovery journey.
Enhanced Disaster Response
Although this syndemic is probably not considered a “typical”
disaster, there are similarities and a potential for learning from disaster
response strategies. When the COVID-19 pandemic began, the closure of
schools, childcare centers, and businesses almost overnight resulted in a
disaster for many individuals and families who suddenly had to balance
decisions about health, childcare, and employment with safety and
socioeconomic security. In 2014, SAMHSA offered a disaster response
strategy focused on trauma-informed care that is particularly suited to this
turbulent time.69 Part of SAMHSA’s recommendations in TIP 57 was to
institute universal screenings and culturally responsive practices in all
healthcare settings69 and in TIP 32 to specifically institute universal
screening for adolescent substance use.70 These are appropriate practices
to adopt now and to continue as part of best practices to better understand
the needs of individuals and provide the most appropriate evidence-based
interventions. Advocacy for resource allocation focused on disasterpreparedness guidelines that include response and recovery is imperative.8
Now is the time to carefully consider the practices, procedures, and policies
that will support a safe and sustained recovery from the syndemic.
Increased Social Vulnerabilities: Clinical Care Pathways
Although our current mental health system was inadequate to
support the needs of our population before the pandemic,33 the syndemic
has highlighted the social disparities and vulnerability that lead to poor
health outcomes. As discussed previously, behavioral health needs have
significantly increased in 2020 at the same time when people are losing jobs
and often the health insurance offered through those jobs. This is an
opportunity to rethink how to address healthcare needs in the US. With
healthcare often tied to employment, this creates additional burdens on the
employer to pay a portion of healthcare costs, restricts the employees’
option to stay with their provider of choice, and significantly increases
healthcare costs with fractured and inconsistent coverage. Improvements
to healthcare coverage should include integrated care systems with
behavioral health and physical health working together to provide the full
spectrum of care. The “acute on chronic” nature of widening health

Published by DigitalCommons@TMC, 2020

11

Journal of Applied Research on Children: Informing Policy for Children at Risk, Vol. 11 [2020], Iss. 2, Art. 7

disparities during COVID-19 complicates access to care for marginalized
populations.71
In 2019, authors publishing in the journal Pediatrics called for
improved public health surveillance to inform clinical guidance for the care
of pregnant woman with a treated or untreated opioid use disorder and their
infants.72 While there were downward trends for pregnant women’s pastmonth reported use of opioids (1.4% in 2017 to 0.4% in 2019), the authors
described shortcomings in the current surveillance system that only
monitors prenatal opioid use, opioid use disorder at delivery, and diagnosis
of neonatal abstinence syndrome. They drew a parallel to the usefulness of
the CDC’s collaboration with health partners to begin mother-infant linked
surveillance during the Zika virus emergency. This surveillance model
allowed for timely information about the impact of infection during
pregnancy which was translated into action and clinical guidance.
Policy
A comprehensive legislative response to increase community
awareness, concern, and action about the heightened risk factors for
substance use across the lifespan is required. This may include heightened
surveillance and monitoring of drug trends, innovative public/private
partnerships to address early use through evidence-based interventions,
and widely disseminated community-based strategies such as mental
health and drug treatment courts. People who use drugs are particularly
vulnerable to infections, decreased immunity, and poor health status, each
of which is exacerbated by barriers to appropriate healthcare services
(including stigma). COVID-19 and public health measures to curtail infection
only increases this vulnerability. The policy interest group of the
International Society of Addiction Medicine recommended development of
a comprehensive healthcare response to improve the detection and
treatment of SUD and COVID-19.73
The newest generation is experiencing increased threats to safety
and security during this pandemic. Developing evidence-based legislation
focused on children and families may help mitigate some of the negative
effects, including maltreatment and mental health sequelae resulting from
stay-at-home orders during COVID-19.42 Approaching this syndemic from a
disaster-response perspective may help relieve some of the psychological
burden.57 Addressing rising suicide rates by implementing new policies and
initiatives requires understanding risk factors that have been exacerbated
by the pandemic. Organizations and communities may benefit from
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collaborating with those with lived experience to embrace system changes
including universal screening and delivery of evidence-based services.74
Legislation covering prescribing MAT for opioid use disorders has
also undergone rapid change in 2020. For example, SAMHSA responded
to the need for safe and effective treatment with methadone by removing
the requirement for in-person daily dosing and removing the requirement
for an in-person physical examination before initiating buprenorphine.75 This
legislation may help reduce virus exposure for people who use drugs as
well as reduce barriers to accessing MAT during the pandemic, but only to
a limited extent. Without full adoption by states and health systems, the
piecemeal implementation of SAMHSA’s guidance will result in continued
fractured services.54 Recent policies such as the expansion of reimbursable
telehealth services, to include psychotherapy and behavioral health
services delivered directly to the patient, are becoming more commonplace
during the pandemic but are not universally adopted. The Center for
Connected Health Policy has a searchable database of telehealth
legislation throughout the US. to share existing models of telehealth
policies.76
One question that remains to be answered is whether the new clinical
care pathways that have been established during COVID-19 will remain in
place or revert to pre-pandemic workflows. This is an important
consideration as the temporary legislative modifications have been
opportunities to test new models of care and provide increased access to
care. Many of these practice transformations have resulted in more efficient
workflow that allows clinicians to focus on patient interactions and supports
the quadruple aim to achieve better outcomes in care for individuals,
healthier populations, better clinician experience, and lower costs. 77 At the
start of the pandemic, primary care sites accounted for less than 1% of
practices that were utilizing telehealth technologies. By April 2020, more
than 43% had adopted telehealth.78

Discussion
The CDC predicts the count of drug overdose deaths from
September 2019 to September 2020 to be 90,237, which is 20,000 more
compared to the prior 12 months.79 While deaths related to synthetic
opioids, including illicitly manufactured fentanyl, were already increasing,
the rapid closure of schools, businesses, and workplaces meant to protect
the population from COVID-19 added additional stressors on already
vulnerable populations. People using drugs or those in recovery were
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suddenly separated from healthcare and other support systems, thereby
increasing the risk of relapse, overdose, and death. Subpopulations, such
as young adults, are of particular importance in that they are particularly
vulnerable to social and psychological disruptions from COVID-19.30 As our
nation sees worsening outcomes related to issues such as domestic
violence, suicidal ideation and suicide attempts/completions, and child
maltreatment, the importance of implementing evidence-based prevention,
intervention, treatment, and recovery models cannot be overstated.
Examples of opportunities across the prevention continuum include
grass-roots organizations led by those with lived experience with
specialization in addiction, mental health, and other conditions with etiology
frequently associated with adverse childhood experiences (ACEs). These
organizations, such as RCOs, fill a niche in communities for those leaving
or transitioning from formal treatment settings.56 While policies and
evidence-based programs can mitigate the traumatic effects of the current
crisis,80 the pandemic has further increased the salience of related
problems.81 Fortunately, there are models for multitiered systems of support
in schools and communities that are inclusive of trauma-informed care
approaches.82 Critical components to effective adoption and dissemination
of all evidence-based models include adequately trained staff and attention
to program fidelity.
The expansion of new technologies and the growing numbers of
community-based organizations offer the opportunity to scale up across all
systems to tailor to the needs of specific populations. Policy changes
during the COVID-19 pandemic reduced barriers to telehealth access and
promoted the use of telehealth as a way to deliver acute, chronic, primary,
and specialty care.83 Telehealth technologies, which allow for visualization
of individuals at their location, provide access to services that may
otherwise not be available. This literal window into a home environment
provides an opportunity for providers to observe risky or unsafe conditions
as well as conduct screenings and counseling interventions using
telehealth modalities.84 Chronic conditions such as cardiovascular
disease, diabetes, depression, anxiety, and substance misuse are likely to
continue worsening as the pandemic continues to disrupt social,
economic, and personal protections. Considering existing models, such as
those implemented to promote disaster preparedness and timely
surveillance of emerging trends, may be useful to improve policies related
to prevention and response.8,16,73 This is the time to innovate in new and
sustained ways to ensure healthy families, communities, and systems that
can effectively respond to the pressing needs of the decade.
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